A Phase 1 Open-Label Dose-Escalation Study of the Safety and Pharmacokinetics of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma.

Trial Profile

A Phase 1 Open-Label Dose-Escalation Study of the Safety and Pharmacokinetics of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2014

At a glance

  • Drugs SNX 5422 (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Esanex
  • Most Recent Events

    • 02 Oct 2014 Status changed from completed to discontinued as per European Journal of Cancer.
    • 24 Sep 2014 Pooled analysis results published in the European Journal of Cancer.
    • 16 May 2012 Company (Esanex) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top